Navigation Links
Micromet Closes $80.5 Million Public Offering of Common Stock
Date:8/4/2009

logy. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, eff
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
2. Micromet Announces Pricing of Public Offering of Common Stock
3. Micromet Announces Public Offering of Common Stock
4. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
5. Micromet Added to Russell 3000 Index
6. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
7. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
8. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
9. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
10. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
11. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... New Haven, Conn. A study by Yale researchers offers ... among individuals suggesting that it is due less to ... that cause extended segments of the human genome to be ... focus for identifying genetic differences has traditionally been on point ...
... As the sizes of sensor networks and mobile devices ... a growing need for suitable power sources. Because even ... in nanoscale devices, scientists are exploring nanosize systems that ... the University of Illinois have shown that a single ...
... ST. LOUIS, Sept. 27 Sigma-Aldrich (Nasdaq:,SIAL) is ... been named the,Vice President of R&D for the ... this role, he will help expand Sigma-Aldrich,s,leadership position ... life science researchers. Sullivan has been involved with ...
Cached Biology Technology:Individual differences caused by shuffled chunks of DNA in the human genome 2Individual differences caused by shuffled chunks of DNA in the human genome 3Nanowire generates power by harvesting energy from the environment 2Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech 2
(Date:7/9/2014)... in which animals can be found, concern mounts over ... increased range for a host mean new territory for ... team of UC Santa Barbara scientists, including parasitologists Ryan ... the Journal of Biogeography , Hechinger, Kuris and ... happen: Hosts may actually lose their parasites when the ...
(Date:7/9/2014)... Tampa, Fla. (July 9, 2014) Emerging fungal ... any other parasitic group, causing population declines of ... from the University of South Florida published in ... amphibians can acquire behavioral or immunological resistance to ... population declines. , "Acquired resistance is important ...
(Date:7/9/2014)... critically ill children with traumatic injuries have identified ... likely to develop a hospital-acquired infection. The study, ... published online in June in the journal ... that could lead to the clinical implementation of ... or reverse immune system damage following critical illness ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... 2010) In the Opening Session of the American ... AAPS President Danny D. Shen, Ph.D., presented the following ... pharmaceutical sciences: Excellence in Ligand-Binding Assay Award ... ANP Technologies, Inc.: Ray Yin; Yli Vallejo; Jing Pan, ...
... what impatiens to plant in your yard, a recent study ... Cajun Carmine, that is if you want fewer insects in ... impatiens attract more thrips than others was one of the ... off by flowers are actually complex compounds known as plant ...
... has been constructed by researchers at the Virginia ... gamma-proteobacteria, a large group of medically and scientifically ... and other disease-causing organisms.* By building powerful phylogenetic ... and differences between the make-up of many different ...
Cached Biology News:AAPS announces 2010 NBC award winners 2When plants attract bugs, it may be their own fault 2When plants attract bugs, it may be their own fault 3New 'Tree of Life' established for one of the largest groups of bacteria 2New 'Tree of Life' established for one of the largest groups of bacteria 3
... Combination inline heater plus multi-channel focal ... drug wash-out with a high-flow bath line ... solutions through the Perfusion Pencil.® Steady 37°C ... the bath line and tip. ...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
Mouse Amphiregulin MAb (Clone 206220)...
Request Info...
Biology Products: